In a recent opinion piece, Joshua Sharfstein critiques Marty Makary's interpretation of the FDA's role in public health.
Sharfstein suggests that Makary's argument fails to recognize the complexities of administrative power and its potential for driving significant reform.
This discussion highlights the ongoing debate about the effectiveness of regulatory bodies in adapting to new challenges.